First Approved Radioligand Therapy for Advanced Prostate Cancer:
India has entered the new phase in precision cancer treatment with the launch of Pluvicto which is the country’s first regulatory authority approved radioligand therapy for the advanced prostate cancer. It is introduced by the Novartis and this therapy offers the highly targeted treatment approach that delivers the radiation directly to cancer cells while minimizing damage to healthy tissues.Pluvicto is the radioligand therapy which is developed for eligible patients suffering from PSMA-positive metastatic prostate cancer.It is specifically designed for those patients whose cancer has spread beyond the prostate gland.This treatment combines the targeting molecule with the radioactive isotope Lutetium-177.This enables the therapy to locate and attack the cancer cells with high precision.
